Bertrand Delsuc, CEO and Founder at Biotellytics, shared a post on X:
“Wow, 2 IO agents discontinued at once by $MRK.
RIP anti TIGIT vibostolimab (2 NSCLC studies of pembro+visbosto declared futile+safety consistent with that observed for vibosto and pembro in previously reported studies (ie not good).
RIP anti LAG3 favezelimab (only 1 ph3 in cHL for pembro+fave) room made for the development of other candidates in $MRK’s comprehensive and diversified oncology pipeline.
Let me guess, like LM-299?
Merck $MRK Provides Update on KeyVibe and KEYFORM Clinical Development Programs Evaluating Investigational Vibostolimab and Favezelimab Fixed-Dose Combinations with Pembrolizumab.”
For more updates, follow OncoDaily.